Hikma Expectations Stabilize – But Generics Still Set To Take A Hit

Firm Cites ‘Strong Momentum’ For Injectables And Branded Divisions

03 Nov 2022

After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.

Hand stops dominoes falling — Hikma has avoided any further falls in its generics guidance • Source: Shutterstock

After issuing two downgrades in guidance for its Generics business across the previous two quarters, Hikma has used its latest trading update to confirm that no further cuts to Generics guidance are expected this year, while the company’s Injectables and Branded segments are enjoying “strong momentum.”

Having started the year by warning of pressures to come on US generics (Also see "Hikma Warns Of Renewed...